Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	3.80B
Revenue (ttm)	1.47B
Net Income (ttm)	170.48M
Shares Out	n/a
EPS (ttm)	0.22
PE Ratio	22.32
Forward PE	n/a
Dividend	0.21 (9.99%)
Ex-Dividend Date	Jul 2, 2024

Volume	42,600
Average Volume	127,985
Open	2.120
Previous Close	2.120
Day's Range	2.120 - 2.150
52-Week Range	1.880 - 2.660
Beta	n/a
RSI	54.17
Earnings Date	Mar 31, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2023, SGX:T14's revenue was 8.22 billion, a decrease of -0.33% compared to the previous year's 8.25 billion. Earnings were 986.71 million, an increase of 14.49%.

Financial numbers in CNY